Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.
about
Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent.Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries.A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse.Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathologyEnhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cellsHuman metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies.
P2860
Q30304128-A0F875CE-EA94-48AF-B167-BCD172C9CB13Q30933288-A83AD64F-9D6B-4FE8-8D8B-6F227BC736B0Q32099239-E334E688-EE90-4F83-ABFE-78E2C4C1DAC4Q33558356-CD527B15-3CB0-4470-894A-ADCE59BA958BQ33648461-B17DC31C-F5D3-4998-8D9B-685EF0C19851Q33807265-C5FC3E88-F91F-4762-890B-21927919A208Q35872191-04C037F0-8863-4785-8E9B-9BE295C27D82Q36005114-63171509-ACF1-4853-A6E4-10DF5C4C4DDBQ36369101-F0EDBDFF-5398-4EA4-AEC5-BBAEF90E0EC9Q36626174-B945B8BF-0630-4C2D-B281-DD70041281BAQ36687435-D6280818-F5A7-4511-BDCB-456A64653CBCQ37683019-90E0EE7A-01DC-495E-A54F-762FDB8F9F24
P2860
Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Serious respiratory tract dise ...... py and effective immunization.
@ast
Serious respiratory tract dise ...... py and effective immunization.
@en
type
label
Serious respiratory tract dise ...... py and effective immunization.
@ast
Serious respiratory tract dise ...... py and effective immunization.
@en
prefLabel
Serious respiratory tract dise ...... py and effective immunization.
@ast
Serious respiratory tract dise ...... py and effective immunization.
@en
P2093
P1433
P1476
Serious respiratory tract dise ...... py and effective immunization.
@en
P2093
P304
P407
P433
P577
1992-07-01T00:00:00Z